Source - LSE Regulatory
RNS Number : 3458O
Deltex Medical Group PLC
17 May 2018

17 May 2018


Deltex Medical Group plc

("Deltex" or "the Company")


Publication of Annual Report and Notification of AGM


Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), gives notice that its Annual Report and Accounts for the year ended 31 December 2017 ("Annual Report & Accounts 2017") has been published on the "Annual & Interim Reports" section of the Company's website at

The Company announced a summary of its results on 9 May 2018 and expects to post printed copies of the Annual Report & Accounts 2017 on 23 May 2018 to shareholders who have informed the Company of their wish to receive reports of this nature in hard copy.

Deltex also announces that its Annual General Meeting will be held at 11:00am on 20 June 2017 at the offices of DAC Beachcroft LLP, 100 Fetter Lane, London EC4A 1BN. The formal notice and resolutions can be found at the back of the Annual Report & Accounts 2017. The related proxy card is expected to be posted on 23 May 2018 to shareholders on the register on 11 May 2018.

For further information, please contact:-


Deltex Medical Group plc                               

01243 774 837

Nigel Keen, Chairman                

Ewan Phillips, Chief Executive   

Jonathan Shaw, Group Finance Director

Nominated Adviser & Broker

Arden Partners plc

020 7614 5900


Chris Hardie

Ciaran Walsh

Joint Broker

Turner Pope Investments (TPI) Ltd

0203 621 4120

Andy Thacker


Financial Public Relations

IFC Advisory Ltd

0203 934 6630


Tim Metcalfe

Graham Herring

Heather Armstrong



Notes for Editors


Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary ODM (TrueVueTM Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only Group in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVueTM Doppler which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.


Deltex Medical's TrueVueTM System on the CardioQ-ODM+ monitor platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.


Group goal


Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Group's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform, a 'haemodynamic workstation', which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition and skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.


This information is provided by RNS
The company news service from the London Stock Exchange
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.